Abstract 350P
Background
Carcinoembryonic antigen (CEACAM) or CD66+ is categorized as type N2 tumour associated neutrophils (TAN), an immunoreceptor expressed on activated neutrophils. It is also known as marker for neutrophil specific granules. This marker is expressed on tumour tissue, has strong immunosuppressive and tumour promoting acttivities including angiogenesis, invasion, and metastasis through various mechanism. This study aimed to assess intratumoural CD66B+ TAN to predict clinical treatment response in patients with diffuse large B cell lymphoma (DLBCL).
Methods
This prognostic study was conducted in Palembang, South Sumatera, Indonesia in 2020. The subjects were 18 - 70 years old DLBCL patients, enrolled by consecutive sampling using medical record. The immunohistochemistry TAN CD66b+ was examined by pathologist. Chemotherapy response was assessed clinically (hematological and radiological) after minimum two cycles of RCHOP regimen. Patients with HIV, relapsed DLBCL, other malignancies, and delayed chemotherapy were excluded.
Results
Of the 21 subjects consisted of 11 men (52,4%), the most subtype (95,2%) was DLBCL non-GCB, prognostic high-risk IPI score 42,9% and intermediate-risk 57,1%. Subjects who achieved complete remission response were 9 people (42,9%). The cut-off value for the CD66b+ TAN density was 21,7 cells/mm2. A total of 76,9% of subjects with high density CD66b+ TAN did not achieve any remission (p=0.029), with sensitivity 83,3% and specificity 66,7%.
Conclusions
We found that density levels of intratumoural CD66b+ TAN in tumour tissue has significant correlation with non-responder (poor prognosis) DLBCL patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract